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Abstract
Background: Recruitment of participants into randomised controlled trials (RCTs) is critical for successful trial conduct.
Although there have been two previous systematic reviews on related topics, the results (which identified specific
interventions) were inconclusive and not generalizable. The aim of our study was to evaluate the relative effectiveness of
recruitment strategies for participation in RCTs.
Methods and Findings: A systematic review, using the PRISMA guideline for reporting of systematic reviews, that compared
methods of recruiting individual study participants into an actual or mock RCT were included. We searched MEDLINE,
Embase, The Cochrane Library, and reference lists of relevant studies. From over 16,000 titles or abstracts reviewed, 396
papers were retrieved and 37 studies were included, in which 18,812 of at least 59,354 people approached agreed to
participate in a clinical RCT. Recruitment strategies were broadly divided into four groups: novel trial designs (eight studies),
recruiter differences (eight studies), incentives (two studies), and provision of trial information (19 studies). Strategies that
increased people’s awareness of the health problem being studied (e.g., an interactive computer program [relative risk (RR)
1.48, 95% confidence interval (CI) 1.00–2.18], attendance at an education session [RR 1.14, 95% CI 1.01–1.28], addition of a
health questionnaire [RR 1.37, 95% CI 1.14–1.66]), or a video about the health condition (RR 1.75, 95% CI 1.11–2.74), and also
monetary incentives (RR1.39, 95% CI 1.13–1.64 to RR 1.53, 95% CI 1.28–1.84) improved recruitment. Increasing patients’
understanding of the trial process, recruiter differences, and various methods of randomisation and consent design did not
show a difference in recruitment. Consent rates were also higher for nonblinded trial design, but differential loss to follow
up between groups may jeopardise the study findings. The study’s main limitation was the necessity of modifying the
search strategy with subsequent search updates because of changes in MEDLINE definitions. The abstracts of previous
versions of this systematic review were published in 2002 and 2007.
Conclusion: Recruitment strategies that focus on increasing potential participants’ awareness of the health problem being
studied, its potential impact on their health, and their engagement in the learning process appeared to increase recruitment
to clinical studies. Further trials of recruitment strategies that target engaging participants to increase their awareness of the
health problems being studied and the potential impact on their health may confirm this hypothesis.
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The randomised controlled trial (RCT) provides the most
reliable evidence for evaluating the effects of health care
interventions [1,2], but the successful conduct of clinical RCTs
is often hindered by recruitment difficulties [3]. Inadequate
recruitment reduces the power of studies to detect significant
intervention effects [4], causes delays (which may affect the
generalizability of the study if standard care changes over time),
increases costs, and can lead to failure to complete trials [5,6].
With increasing reliance on clinical RCT findings for clinical and
regulatory decision making, the success of future RCTs depends
on employing effective and efficient methods for recruiting study
participants [7].
Historically recruitment of participants for RCTs has been by
‘‘trial and error’’ [8], by using a number of different strategies and
modifying strategies according to the observed effects on
recruitment. More recently, novel strategies have been developed
to facilitate adequate and timely recruitment [3,4]. Although there
have been two previous systematic reviews on strategies to
enhance recruitment to research [9,10], they identified specific
individual interventions. However, these interventions could not
be combined to offer useful general advice for recruitment for
clinical RCTs.
The aim of this study was to identify effective recruitment
strategies for clinical RCTs by systematically reviewing rando-
mised studies that compare consent rates, or other methods of
measuring consent for two or more recruitment methods used, to
approach potential RCT participants for trial participation (these
studies are termed recruitment trials).
Methods
A protocol for this systematic review had not been registered
before the review commenced, although the abstracts of previous
versions of this systematic review were published in 2002
(International Clinical Trials Symposium: improving health care
in the new millennium) [11] and 2007 (3rd International Clinical
Trials Symposium) [12] (Text S1).
Selection Criteria
All randomised and quasi-randomised studies that compared
two or more methods of recruiting study participants to a real
phase III RCT or mock RCT (where no actual trial occurred)
were included. Studies that assessed recruitment to observational
studies, questionnaires, health promotional activities, and other
health care interventions and nonrandomised studies of recruit-
ment strategies were excluded. Where more than one publication
of the same study existed, the publication with the most complete
data was included.
Literature Search
Studies were identified from MEDLINE (1950 to April, week 4,
2009), Embase (1980 to week 17, 2009),and The CochraneLibrary
(Cochrane Library, issue 3, 2009) (Figure 1). The MEDLINE and
Embase databases were searched using text words and subject
headings (with unlimited truncations) for ‘‘recruitment,’’ ‘‘enrol-
ment,’’ and ‘‘accrual’’ combined with ‘‘random’’ and ‘‘trials’’ and
‘‘participate’’ or ‘‘consent’’ or ‘‘recruit’’ with unlimited truncations.
The Cochrane Library was searched using ‘‘recruitment’’ com-
bined with ‘‘random and trial,’’ and ‘‘consent or accrual.’’ The
search strategy changed slightly with time as a result of changes in
MEDLINE Mesh heading definitions. Reference lists of relevant
studies were also searched and non-English language papers were
translated. Two of three reviewers (PHYC, AT, or SH) indepen-
dently screened each study title and abstract for eligibility, retrieved
full text articles of allpotentially relevantstudies, and extracteddata
from the retrieved papers using a form that was designed by the
authors. Disagreements were resolved by discussion with a third
reviewer (JCC).
Data Extraction
Data were extracted without blinding to authorship, on the
recruitment methods evaluated, the population setting, and the
trial design, as well as risk of bias items such as randomisation,
allocation concealment, blinding of outcome assessors, loss to
follow up, and intention-to-treat analysis. These elements were
each assessed separately using the method developed by the
Cochrane Collaboration [13].
Outcomes Assessed
The primary outcome of interest was consent rates for the
different recruitment strategies. Because studies differed in
definitions of consent rates, where possible we recalculated the
consent rate of each recruitment method by dividing the number
of participants exposed to the recruitment method who actually
consented for clinical study participation by the total number of
potential participants exposed to that method (see Figure 2). For
studies where information was insufficient to calculate consent
rates, other measures of consent success described in the study
were reported. For mock trials, willingness to consent to
participate (i.e., potential participants acknowledging that they
would be willing to participate in the trial or willingness to be
contacted for participation in future trials) was the outcome
measure. Consent rates and other outcome measures were
compared using intention-to-treat analysis.
Statistical Methods
Where possible we used relative risk (RR) and their 95%
confidence intervals (CIs) to describe the effects of different
strategies in individual recruitment trials. Where more than two
strategies were used in a single recruitment trial, the numerator
and denominator from the standard (control) recruitment strategy
was divided by the number of intervention strategies for each
comparison so that the control numbers would not be overrep-
resented [13].
Results
Literature Search
From 16,703 unique titles and abstracts, 396 articles were
retrieved and 37 eligible publications identified (Figure 1).
Collectively this total assessed recruitment outcomes in at least
59,354 people who were approached for clinical study participa-
tion, of whom 18,812 consented to participate (Table 1). (Not all
studies identified the number of potential participants who were
approached).
Quality of Included Studies
There were 23 parallel group RCTs, six quasi-RCTs (including
one using paired data), and eight cluster RCTs. Of the 37
included recruitment trials, only 12 studies (32%) had clear
allocation concealment, two (4%) specified blinding of outcome
assessors (no study had blinding of participants as this would have
been difficult to achieve), 15 (40%) recorded loss to follow-up
information, and 14 (38%) used intention-to-treat analysis (see
Table 2).
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Of the 37 included studies, 17 assessed treatment comparisons,
11 were prevention studies, and nine mock studies (where
participants declared their willingness to participate in a trial but
no actual trial occurred).
There were 66 different types of recruitment strategies that were
broadly categorised into four groups: novel trial designs (nine
studies), recruiter differences (eight studies), incentives (two
studies), and provision of trial information (19 studies), with one
study looking at both novel trial design and incentives [14].
Standard recruitment is defined as when the investigator invites
the potential participant to enrol in the study and treatment
allocation is randomly assigned after consent has been given, with
routine treatment being provided where consent is not given.
Types of Recruitment Strategies Studied
Novel trial designs. Avenell and Hemminki [15,16]
compared a standard placebo-controlled design with a non-
blinded trial design (both for prevention studies) (see Figure 3 and
Table 3). In the nonblinded trial design arm, randomisation
occurred before participants were approached, and participants
were informed of the treatment they were randomised to receive
prior to giving consent. Consent rates were higher for the
nonblinded trial design compared with standard trial design
where randomisation occurred after consent for trial participation
(RR 1.14, 95% CI 1.02–1.28 and RR 1.28, 95% CI 1.19–1.37,
respectively) [15,16]. Welton [17] compared a noninferiority
clinical study (where both arms of the trial had an active
treatment) with a placebo-controlled study of hormone replace-
ment for postmenopausal women. Willingness to enrol in the
clinical study appeared to be higher for the noninferiority study
compared with the placebo-controlled study, although results were
only just statistically significant (39% versus 30%, RR 1.31, 95%
CI 1.01–1.70).
Gallo and Myles (both for mock studies) compared standard
randomisation (random assignment for all participants and
standard care for nonparticipants) with different types of
Figure 1. Literature search.
doi:10.1371/journal.pmed.1000368.g001
Figure 2. Consent rate for RCTs.
doi:10.1371/journal.pmed.1000368.g002
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Trial
Type Author
Year of
Publication
Country
of Trial
Health
Problem
Studied
Intervention
Arms of RCT
Recruitment
Strategy
Studied
n Recruited
for Trial
n Invited to
Participate
in Trial
Treatment Du [39] 2008 USA Lung
cancer
Mixed treatments
(multiple trials)
Information
provision
26 126
Hutchison
[38]
2007 UK Multiple
cancers
Mixed treatments
(multiple trials)
Information
provision
128 173
Monaghan
[51]
2006 Multinational BP control
in diabetics
Antihypertensive
versus placebo
Recruiter
differences
7,847 167 sites
Litchfield
[42]
a
2005 UK Diabetes Two insulin
delivery systems
Recruiter
differences
73 80
Kimmick
[40]
2005 USA Multiple
cancers
Mixed treatments
(multiple trials)
Recruiter
differences
1,097 unknown
Nystuen
[31]
2004 Norway Absentee
employees
Follow up versus
standard care
Information
provision
97 703
Donovan
[23]
2003 UK Prostate
cancer
Surgery versus
radiotherapy
versus monitoring
Recruiter
differences
103 150
Coyne
[48]
2003 USA Multiple
cancers
Chemotherapy
(multiple trials)
Information
provision
147 226
Quinaux [41] 2003 France Breast cancer Chemotherapies Recruiter
differences
362 unknown
Tworoger
[37]
2002 USA Breast cancer Aerobic exercises
versus stretching
Information
provision
376 4,999
Fleissig
[49]
2001 UK Multiple
cancers
Mixed treatments
(multiple trials)
Recruiter
differences
205 265 (15
recruiters)
Miller
[43]
1999 USA Depression Psychotherapy
versus antidepressants
versus both
Recruiter
differences
50 347
Cooper
[22]
1997 UK Menorrhagia Medical management
versus surgery
Trial design 187 273
Berner
[45]
1997 USA Gynaecological
cancers
Mixed treatments
(multiple trials)
Information
provision
91 2 0
Aaronson
[20]
1996 The
Netherlands
Multiple
cancers
Chemotherapy
(multiple trials)
Information
provision
146 346
Wadland
[35]
1990 USA Smoking Nicotine gum versus
standard care
Information
provision
52 104
Simes
[33]
1986 Australia Multiple
cancers
Mixed treatments
(multiple trials)
Information
provision
50 57
Prevention Leira
[29]
2009 USA Aspiration
pneumonia
Ranitidine versus
placebo
Information
provision
52 100
Mandelblatt
[3]
a
2005 USA Breast
cancer
Tamoxifen versus
Raloxifene
Information
provision
325 450
Avenell
[21]
a
2004 UK Fractures Vitamins versus
placebo/no treatment
Trial design 367 538
Ford
[25]
2004 USA Multiple
cancers
Screening tests versus
standard care
Information
provision
376 12,400
Hemminki
[27]
a
2004 Estonia Postmenopausal
health risks
Hormone replacement
versus placebo/ no
treatment
Trial design 1,823 4,295
Larkey
[50]
2002 USA cardiovascular
disease, cancer
and osteoporosis
Hormone replacement
therapy and dietary
modification and
calcium and vitamin
D supplements
Recruiter
differences
13 34+
Kendrick
[4]
2001 UK Home safety Safety equipment
versus usual care
Information
provision
374 2,397
Kiernan
[28]
2000 USA Healthy diet Additional goal
setting techniques
versus standard care
Information
provision
95 6 1
Recruitment Strategies for Trials
PLoS Medicine | www.plosmedicine.org 4 November 2010 | Volume 7 | Issue 11 | e1000368randomisation designs [18,19]. Strategies included increasing or
decreasing the chance of receiving the experimental treatment;
experimental treatment for all participants and standard treatment
for nonparticipants (where potential participants are informed that
they have been randomised to receive the experimental treatment,
but if they do not consent, they would receive the standard
treatment); standard care for all participants and experimental
treatment for nonparticipants (where potential participants are
informed that they have been randomised to receive the standard
treatment, but if they do not consent, they would receive the
experimental treatment); and random assignment of treatment for
participants and choice of treatment for nonparticipants. The only
randomisation strategy that influenced consent was the ‘‘pre-
randomisation to standard drug’’ (standard care for all participants
and experimental treatment for nonparticipants) in Gallo’s study
[18], which significantly reduced the consent rate compared with
standard randomisation (RR 0.60, 95% CI 0.53–0.69) [18].
However, this was not demonstrated in Myles’ study [19].
Cooper compared standard consent with partially randomised
patient preference where patients could choose to be randomised
or choose their own (medical or surgical) treatment [20]. Patients
who chose their own treatment were excluded in our analysis, as
choice of treatment conflicts with the purposes of random
allocation of treatment, and only patients who chose to be
randomised were compared with those receiving standard RCT
consent (where they were offered the opportunity to participate in
a clinical study where treatment was randomly allocated for
participants). This study tested whether allowing a patient choice
of treatments increased consent for choosing to have their
treatment randomised, compared with simply inviting them to
participate in a clinical RCT (without mentioning choice of
treatment). There was no difference in consent rates between the
standard consent and choosing to be randomised (RR 0.95, 95%
CI 0.81–1.11).
Rogers compared ‘‘opting in’’ with ‘‘opting out’’ [21] where
consent was sought for participation or for nonparticipation,
respectively. In the ‘‘opting out’’ arm, consent rate for clinical
study participation was calculated as the proportion who did not
sign the consent form (for refusing participation). There was no
difference in consent rates between the two groups (RR 1.07, 95%
CI 0.81–1.41).
Simel compared consenting to a clinical study assessing
standard medication versus a new medication that worked twice
as fast with a clinical study comparing standard medication with a
new medication that worked half as fast as the standard
medication [22]. Participants were not informed that this was a
mock trial. This study was designed to assess patients’ competence
and judgement regarding clinical study participation. Not
surprisingly, more patients consented to a clinical study comparing
the faster new medication than to a clinical study comparing a
slower new medication (67% versus 41%, RR 0.62, 95% CI 0.42–
0.91), with a more marked difference among those who voluntarily
Trial
Type Author
Year of
Publication
Country
of Trial
Health
Problem
Studied
Intervention
Arms of RCT
Recruitment
Strategy
Studied
n Recruited
for Trial
n Invited to
Participate
in Trial
Welton
[46]
a
1999 UK menopausal
symptoms and
osteoporosis
Hormone replacement
therapies versus placebo
Trial design 150 492 (438)
Rogers
[32]
1998 USA Risk for life
threatening illness
Follow up versus
standard care
Trial design 44 57
Valanis
[34]
1998 USA Lung cancer Vitamins versus
placebo
Information
provision
451 22,546
Mock trial Halpern
[47]
2004 USA Hypertension Different
hypertensives
Incentives+trial
design
66–94 142
Ellis
[24]
2002 Australia Breast cancer Chemotherapy
versus Tamoxifen
Information
provision
26 180
Martinson
[6]
a
2000 USA Smoking cessation
and prevention
Peer, mail, and phone
contacts versus
standard care
Incentives 1,560 4,046
Wragg
[44]
2000 UK Postmenopausal
health risks
Hormone replacement
versus placebo
Information
provision
22 50
Myles
[30]
1999 Australia Anaesthesia for
surgery
Experimental drug
versus standard care
Trial design 429 770
Weston
[5]
a
1997 Canada Premature labour Induced labour versus
expectant management
Information
provision
43 90
Gallo
[26]
a
1995 Italy Hypothetical
disease
Experimental drug
versus standard drug
Trial design 1,620 2,035
Llewellyn-
Thomas [2]
a
1995 Canada Bowel cancer Chemotherapy
versus monitoring
Information
provision
52 102
Simel [36]
a 1991 USA Variable presenting
health problems
Standard versus
new medication
Trial design 55 100
Total 18,812 59,354+
aStudies showed a statistically significant difference in consent rates between recruitment strategies.
BP, blood pressure.
doi:10.1371/journal.pmed.1000368.t001
Table 1. Cont.
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decision regarding clinical study participation, which may reflect
better understanding of the trial information.
Halpern [14] used a factorial design to assess willingness to
participate in a number of mock trials using paired data from the
same individuals with variations in clinical study designs (as well as
variation in monetary incentives, which will be discussed later
under ‘‘incentives’’). There were no differences in consent rates
statistically.
Recruiter differences. Eight recruitment trials compared
recruiter differences (see Figure 4 and Table 4). Three cluster
RCTs compared different strategies for engaging recruiters (e.g.,
standard contact versus additional monitoring and contact with
recruiters [23–25]). Outcome measures were different for each of
the studies and therefore results could not be combined. In
Quinaux’s study, 186 patients from 34 control centres enrolled
compared with 176 total patients from 34 monitored centres [23].
In Kimmick’s study, 1,161 elderly patients (36% of total patients in
first year and 31% in second year) from the control centres
enrolled compared with 1,075 (32% in first year and 31% in
second year) from the centres who received additional training and
contact with investigators [24]. Monaghan’s study assessed median
Table 2. Quality of included studies.
Trial Type Author
Type
Of RCT
Allocation
Concealment
Blinding of
Outcome
Assessors
Loss to Follow
Up Mentioned
Intention-to-
Treat Analysis
Quality
Items
Prevention Avenell [21] Parallel Yes No Yes Yes 3
Prevention Rogers [32] Parallel Yes Yes No Yes 3
Treatment Monaghan [51] Cluster RCT Yes Unclear Unclear Yes 2
Treatment Hutchison [38] Parallel Yes Unclear Unclear Yes 2
Treatment Cooper [22] Parallel Yes No No Yes 2
Treatment Tworoger [37] Parallel Unclear Unclear Yes Yes 2
Treatment Coyne [48] Cluster RCT Unclear No Yes Yes 2
Treatment Du [39] Parallel Unclear Yes Yes No 2
Prevention Kendrick [4] Parallel Yes No Yes Unclear 2
Prevention Hemminki [27] Parallel Yes No Unclear Yes 2
Prevention Ford [25] Parallel Unclear No Yes Yes 2
Prevention Leira [29] Parallel No Unclear Yes Yes 2
Mock trial Weston [5] Parallel Yes No Yes Unclear 2
Mock trial Ellis [24] Parallel Yes No Yes Unclear 2
Mock trial Llewellyn-Thomas [2] Parallel Yes No Yes No 2
Mock trial Martinson [6] Cluster RCT Yes No Unclear Yes 2
Treatment Donovan [23] Parallel Yes No No No 1
Treatment Wadland [35] Parallel Unclear No Yes Unclear 1
Treatment Aaronson [20] Parallel Unclear No Yes Unclear 1
Treatment Berner [45] Quasi-RCT No Unclear Yes Unclear 1
Treatment Nystuen [31] Parallel No Unclear Unclear Yes 1
Prevention Larkey [50] Cluster RCT Unclear No Yes No 1
Prevention Valanis [34] Parallel Unclear No No Yes 1
Prevention Welton [46] Quasi-RCT No No Yes Unclear 1
Mock trial Simel [36] Parallel Unclear No No Yes 1
Treatment Quinaux [41] Cluster RCT Unclear Unclear Unclear Unclear 0
Treatment Kimmick [40] Cluster RCT Unclear Unclear Unclear Unclear 0
Treatment Litchfield [42] Cluster RCT Unclear Unclear Unclear Unclear 0
Treatment Fleissig [49] Cluster RCT Unclear No No Unclear 0
Treatment Simes [33] Parallel No No No Unclear 0
Treatment Miller [43] Quasi-RCT No No No Unclear 0
Prevention Kiernan [28] Parallel Unclear No No Unclear 0
Prevention Mandelblatt [3] Quasi-RCT No No Unclear Unclear 0
Mock trial Gallo [26] Parallel Unclear No No Unclear 0
Mock trial Myles [30] Parallel Unclear No No Unclear 0
Mock trial Wragg [44] Quasi-RCT Unclear No No Unclear 0
Mock trial Halpern [47] Paired data No No Unclear Unclear 0
doi:10.1371/journal.pmed.1000368.t002
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control sites compared with 37.5 patients from the 85 sites with
increased contacts with investigators [25]. In all three studies,
increased contact with investigators did not statistically increase
consent rates, and appeared to actually lower enrolment. One
recruitment trial that compared untrained recruiters with training of
recruiters [26] found statistically more patients enrolled when the
recruiter was trained (28 trained recruiters enrolled 13 patients versus
28 untrained recruiters who enrolled no patients). Fleissig compared
standard recruitment with providing recruiters with information
about patient preferences [27], with no differences in consent rates
between the two methods (RR 1.09, 95% CI 0.96–1.25).
Donovan and Miller compared recruiter roles (doctor versus
nurse RR 0.94, 95% CI 0.76–1.17 [28], and senior investigator
versus research assistant RR 0.69, 95% CI 0.41–1.15 [29]).
Although there was no difference in consent rates between the
recruiters, costs were higher for the more senior person (mean cost
of £43.29 versus £36.40 and US$78.48 versus US$50.28 per
patient randomised, respectively).
Litchfield compared internet-derived database handling with
paper-based database handling [30]. Although proportionately
more patients enrolled with the paper-based database, the internet
database was more efficient (with shorter time required for data
collection and more patients being exposed to the trial). 100% of
paper-based database versus 87% internet database groups
enrolled (RR 0.87, 95% CI 0.78–0.96), with the internet database
being preferable for recruiters.
Incentives. Martinson and Halpern assessed incentives for
increasing recruitment (see Figure 5 and Table 5) [14,31]. In the
Martinson study, compared to no incentives, any monetary
incentive increased survey response rates and willingness to be
contacted regarding a smoking cessation trial. The study did not
measure actual recruitment to the clinical study. Consent rate for
no incentives was 29% compared with 41% for prepaid US$2 cash
incentive (RR 1.43, 95% CI 1.19–1.72); 44% for US$15 cash
incentive contingent on completion of survey (RR 1.53, 95% CI
1.28–1.84); and 39% for US$200 prize draw (RR 1.36, 95% CI
1.13–1.64).
The Halpern study assessed the effect of variations in monetary
incentives on the willingness to participate in a number of mock
clinical studies (of varying trial designs that was mentioned earlier).
Patients’ willingness to participate increased as the payment level
increased from US$100 to US$2,000 irrespective of the risk of
adverse effect and risk of being assigned to placebo, although the
difference was not statistically significant.
Methods of providing information. Nineteen recruitment
trials compared different methods of providing information to
participants, including how the information was presented and
what information was provided (see Figure 6 and Table 6).
There were six recruitment trials that related to mailing of
recruitment material for the clinical study. The methods used to
enhance recruitment were the addition of: a questionnaire that
focused on the health problem studied (Kendrick [32]); a personal
letter inviting participation (Kiernan and Tworoger [33,34]); use
of bulk mailing or first class stamps (Tworoger [34]); an advanced
postcard alerting recipients to look for the recruitment packet
(Valanis [35]); a reminder phone call for nonresponders of mailed
recruitment material (Nystuen [36]); and increasingly intensive
interventions (for African Americans), which included a follow-up
eligibility-screening phone call, an enhanced recruitment letter
featuring a prominent African American man, recruitment by an
African American member of the research team, and involvement
of church-based project sessions (Ford [37]). Kendrick’s addition
of the questionnaire that focused on the health problem studied
(RR 1.37, 95% CI 1.14–1.66) [32] was the only mailing strategy
that increased the consent rate compared with standard mailing of
recruitment material. The personal letter [33,34] using bulk mail
or first class mail [34], advanced postcard warning [35], and
reminder phone calls [36] did not significantly increase consent
rates (see Table 6).
Leira compared standard consent (being invited to participate in
the clinical study when the investigators met the patient during
helicopter retrievals) with advanced notification of the clinical
study with telephone and faxing of informed consent documents
prior to arrival of investigators in the helicopter [38]. The
intention-to-treat analysis showed no statistical difference between
the two recruitment strategies (RR 1.08, 95% CI 0.74–1.57),
although 42% of the intervention group did not actually receive
the intervention (fax and telephone call) because of technical and
logistic reasons. Coyne compared an easy-to-read consent
statement with standard consent [39] but showed no significant
difference in consent rates (RR 1.11, 95% CI 0.94–1.31).
Figure 3. Consent rates for novel trial designs. RR, intervention recruitment strategy/standard recruitment strategy. Used total number/number
of intervention strategies to calculate RR, so that the number of patients on standard strategies were not overrepresented; S, random assignment for
participants, standard care for nonparticipants; 2, patients are told physician believes the experimental drug may be superior. Increased chance of
receiving the experimental drug after consenting; 3, patients are told that they are allowed to increase or decrease their chance of receiving the new
experimental drug after consenting; 4, experimental drug for participants, standard care for nonparticipants; 5, standard drug for participants,
experimental drug for nonparticipants; 6, random assignment for participants, choice of either treatments for nonparticipants.
doi:10.1371/journal.pmed.1000368.g003
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Study
Standard Recruitment
Strategy n/N
Consent Rate
(95% CI)
Experimental Recruitment
Strategies n/N
Consent Rate
(95% CI)
RR
(95% CI)
Myles [30] One-sided informed
consent
a
84/151 56% (48–64) One-sided physician
modified
b
91/150 61% (52–69) 1.10
(0.80–1.50)
One-sided patient
modified
c
85/150 57% (48–65) 1.03
(0.75–1.41)
Prerandomised to
experimental drug
d
90/169 53% (45–61) 0.96
(0.70–1.33)
Prerandomised to
standard drug
e
79/149 53% (45–61) 0.96
(0.69–1.33)
Gallo [26] One-sided informed
consent
a
521/622 84% (81–87) Prerandomised to
experimental drug
d
642/730 88% (86–90) 1.05
(0.98–1.12)
Prerandomised to
standard drug
e
156/307 51% (45–56) 0.60
(0.53–0.69)
f
Two-sided informed
consent
g
301/376 80% (76–84) 0.95
(0.88–1.03)
Avenell [21] Standard placebo-
controlled design
233/358 65% (60–70) Nonblinded trial
design
134/180 74% (67–81) 1.14
(1.02–1.28)
f
Hemminki [27] Standard placebo-
controlled design
796/2,136 37% (35–39) Nonblinded trial
design
1,027/2159 48% (46–50) 1.28
(1.19–1.37)
f
Rogers [32] Opting-in consent for
participation
24/32 75% (57–89) Opting-out consent
for nonparticipation
20/25 80% (59–93) 1.07
(0.81–1.41)
Cooper [22] Standard informed
consent
97/138 70% (62–78) Partially randomised
patient preference
h
90/135 67% (58–75) 0.95
(0.81–1.11)
Simel [36] Consent for trial of usual
treatment versus new
treatment that may work
twice as fast
35/52 67% (53–80) Consent for trial of usual
treatment versus new
treatment that may
work half as fast
20/48 41% (28–57) 0.62
(0.42–0.91)
f
Halpern [47] A-
US$100 incentive
10% risk of adverse
effects
26/64 41% (29–54) 20% risk of adverse
effects
23/64 36% (24–49) 1.08
(0.59–2.00)
10% risk of adverse
effects
26/64 41% (29–54) 30% risk of adverse
effects
18/64 28% (18–41) 1.44
(0.72–2.89)
20% risk of adverse
effects
23/64 36% (24–49) 30% risk of adverse
effects
18/64 28% (18–41) 1.33
(0.65–2.72)
Halpern [47] A-
US$1,000 incentive
10% risk of adverse
effects
33/64 52% (39–64) 20% risk of adverse
effects
26/64 41% (29–54) 1.31
(0.77–2.22)
10% risk of adverse
effects
33/64 52% (39–64) 30% risk of adverse
effects
23/64 36% (24–49) 1.42
(0.81–2.46)
20% risk of adverse
effects
26/64 41% (29–54) 30% risk of adverse
effects
23/64 36% (24–49) 1.08
(0.59–2.00)
Halpern [47] A-
US$2,000 incentive
10% risk of adverse
effects
35/64 55% (42–67) 20% risk of adverse
effects
29/64 45% (33–58) 1.20
(0.74–1.94)
10% risk of adverse
effects
35/64 55% (42–67) 30% risk of adverse
effects
25/64 39% (27–52) 1.38
(0.82–2.33)
20% risk of adverse
effects
29/64 45% (33–58) 30% risk of adverse
effects
25/64 39% (27–52) 1.15
(0.66–2.02)
Halpern [47] B-
US$100 incentive
10% assigned to
placebo
21/62 34% (22–47) 30% assigned to
placebo
20/62 32% (21–45) 1.10
(0.55–2.21)
10% assigned to
placebo
21/62 34% (22–47) 50% assigned to
placebo
19/62 31% (20–44) 1.10
(0.55–2.21)
30% assigned to
placebo
20/62 32% (21–45) 50% assigned to
placebo
19/62 31% (20–44) 1.00
(0.49–2.06)
Halpern [47] B-
US$1,000 incentive
10% assigned to
placebo
27/62 44% (31–57) 30% assigned to
placebo
25/62 40% (28–54) 1.08
(0.61–1.90)
10% assigned to
placebo
27/62 44% (31–57) 50% assigned to
placebo
23/62 37% (25–50) 1.17
(0.65–2.10)
30% assigned to
placebo
25/62 40% (28–54) 50% assigned to
placebo
23/62 37% (25–50) 1.08
(0.59–1.99)
Halpern [47]
B- US$2,000
incentive
10% assigned to
placebo
28/62 45% (33–58) 30% assigned to
placebo
26/62 42% (30–55) 1.08
(0.61–1.90)
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understanding of the clinical trial process, which did not appear
to affect recruitment [40–42]. Ellis compared standard informed
consent with the addition of an educational booklet on clinical
trials [40]. There was no difference in consent rates (unadjusted)
between the two groups (RR 0.88, 95% CI 0.46–1.66). However,
after adjusting for potential confounders (demographic variables,
disease variables, preference for involvement in clinical decision
making, anxiety, depression, and attitudes to clinical trials),
participants receiving the educational booklets were significantly
less likely to consent to clinical study participation (OR 0.22, 95%
CI 0.04–1.0). Du compared standard care with the addition of a
brief video about cancer clinical studies among patients with lung
cancer [41]. Consent rates were not statistically different between
the two groups. Hutchison compared standard care (where
patients discuss clinical care and clinical study participation with
the administration of a trial-specific information sheet and consent
form) with the addition of an audiovisual patient information tool
(with choice of video, CD-Rom, or DVD format), which addressed
clinical trial information [42], with no difference in consent rates
between the two groups (76% versus 72%, RR 0.95, 95% CI
0.80–1.13).
Three recruitment trials assessed strategies that aim to increase
participants’ understanding of their underlying condition. Llewel-
lyn-Thomas compared tape recorded reading of clinical study
information with an interactive computer program where
participants (who were oncology patients receiving radiation
therapy) were actively involved in the information search process
[43]. The consent rate was higher for participants in the
interactive group (RR 1.48, 95% CI 1.00–2.18). Weston compared
standard informed consent with the addition of a video explaining
trial information and the health problem studied [44]. The
consent rate was higher in the video group when initially assessed
(RR 1.75, 95% CI 1.11–2.74), but this did not reach statistical
significance at 2 wk follow-up (not shown on Table 6). Berner’s
recruitment trial compared standard care (verbal communication)
with the addition of patient information files containing clinical
information on cancer specific to the patient [45]. There was no
difference in the rate of recruitment to cancer trials in both groups
(7% versus 7%, RR 0.89, 95% CI 0.24–3.38), although not all
patients were eligible for clinical study enrolment.
Three recruitment trials compared standard consent with
additional personal contact with research staff (a study coordinator
reading and explaining the clinical study, Wadland [46];
additional phone-based contact with an oncology nurse, Aaronson
[47]; and an additional educational session about the disease and
risks and benefits of clinical study participation for an oncology
prevention study, Mandelblatt [48]). There was no difference in
consent rates between standard consent and the study coordinator
reading and explaining the clinical study (RR 1.12, 95% CI 0.76–
1.65) [46] or additional phone-based contact with the oncology
nurse (RR 0.87, 95% CI 0.76–1.01) [47]. However there was
higher consent for participants who attended the education session
(RR 1.14, 95% CI 1.01–1.28) [48].
There were two recruitment trials assessing framing of
recruitment information. In Simes’ 1986 trial of recruitment for
a cancer treatment study [49], total disclosure of information
about the clinical study was compared with an individual
Study
Standard Recruitment
Strategy n/N
Consent Rate
(95% CI)
Experimental Recruitment
Strategies n/N
Consent Rate
(95% CI)
RR
(95% CI)
10% assigned to placebo 28/62 45% (33–58) 50% assigned to placebo 27/62 44% (31–57) 1.00
(0.58–1.73)
30% assigned to placebo 26/62 42% (30–55) 50% assigned to placebo 27/62 44% (31–57) 0.93
(0.53–1.64)
Welton [46] Standard placebo-
controlled design
65/218 30% (24–36) Noninferiority trial design 85/218 39% (33–46) 1.31
(1.01–1.70)
f
RR, experimental recruitment strategy/standard recruitment strategy. Used total number/number of experimental strategies to calculate RR, so that standard was not
overrepresented. Halpern’s study used each participant more than once.
aRandom assignment for participants, standard care for nonparticipants.
bPatients told physician believes the experimental drug may be superior. Increased chance of receiving the experimental drug after consenting.
cPatients are told that they are allowed to increase or decrease their chance of receiving the new experimental drug after consenting.
dExperimental drug for participants, standard care for nonparticipants.
eStandard drug for participants, experimental drug for nonparticipants.
fStudies showed a statistically significant difference in consent rates between recruitment strategies.
gRandom assignment for participants, choice of either treatments for nonparticipants.
hPatients could choose to be randomised or choose their own treatment, but only those who chose to be randomised were compared with standard treatment.
doi:10.1371/journal.pmed.1000368.t003
Table 3. Cont.
Figure 4. Consent rates for recruiter differences. RR, intervention recruitment strategy/standard recruitment strategy.
doi:10.1371/journal.pmed.1000368.g004
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in a manner they thought best. This study assessed both
willingness to enrol in the clinical study and actual study
participation. There were no differences in actual consent rates
between the total disclosure and individual approach groups (RR
1.13, 95% CI 0.93–1.38). However, actual consent rates were
higher than the stated willingness to participate in the clinical
study (actual consent rates were 82% and 93% in the total
disclosure and individual approach groups, respectively, compared
with rates of 65% and 88%, respectively, for willingness to
participate in the clinical study). Wragg compared framing of
recruitment information explicitly (to provide the best current
estimates of effect for the experimental treatment) with framing
information ambiguously (to emphasise the uncertainty and
relative costs and benefits of the experimental treatment) [50].
There was no difference in consent rates between the ‘‘ambigu-
ously framed’’ group and the ‘‘explicitly framed’’ group (RR 1.90,
95% CI 0.97–3.70).
Discussion
Trials of recruitment strategies have evaluated all steps in the
recruitment process, including different methods of trial design,
randomisation, provision of information, and recruiter differences.
In this systematic review, we found that strategies that increased
potential participants’ awareness of the health problem being
studied by engaging them in the learning process significantly
increased consent rates (both for ‘‘real’’ and mock trials). These
strategies included the addition of a questionnaire that focused on
the health problem studied and additional educational sessions,
videos, and interactive programs about the diseases studied
[32,43,44,48]. Strategies that increased understanding of the
clinical trial process (e.g., provision of an educational booklet [40],
video [41], or audiovisual patient information tool [42] on clinical
trials or provision of an easy-to-read consent statement [39])
showed no evidence of improved recruitment. This finding
suggests that it is increased education about the health problem
Figure 5. Consent rates for incentives. RR, intervention recruitment strategy/standard recruitment strategy. Used total number/number of
intervention strategies to calculate RR, so that the number of patients on standard strategies were not overrepresented; S, random assignment for
participants, standard care for nonparticipants; 1, small incentives (US$2 prepaid cash incentive); 2, larger incentive (US$15) contingent on response;
3, US$200 prize draw.
doi:10.1371/journal.pmed.1000368.g005
Table 4. Studies of recruiter differences.
Study
Standard Recruitment
Strategy n/N
Consent Rate
(95% CI)
Experimental
Recruitment Strategies n/N
Consent Rate
(95% CI)
RR
(95% CI)
Donovan [23] Recruitment by
urologist
53/75 71% (59–81) Recruitment by nurse 50/75 67% (55–77) 0.94
(0.76–1.17)
Miller [43] Recruitment by senior
investigator
28/162 17% (12–24) Recruitment by research
assistant
22/185 12% (8–17) 0.69
(0.41–1.15)
Fleissig [49] Standard consent,
doctors not aware of
patients’ personal
preferences
96/130 74% (65–81) Doctors shown patient’s
responses to questionnaire
regarding personal
preferences and trial
participation before
recruiting patients for trial
109/135 81% (73–87) 1.09
(0.96–1.25)
Litchfield [42] Paper-based data
recording
28/28 screened 100% (88–100) Internet data capture 45/52 screened 87% (74–94) 0.87
(0.78–0.96)
a
Quinaux [41] Centres not monitored 186/34 centres Monitored centres 176/34 centres
Larkey [50] Recruiters not trained 0/28 recruiters Recruiters trained 13/28 recruiters
Kimmick [40] Standard recruitment,
website access and
periodic notification
777 (year 1)+384
(year 2)=1,161
Additional seminar,
educational materials,
list of available protocols,
email and mail reminders,
and case discussion
seminars for recruiters
691 year 1)+384
(year 2)=1,075
Monaghan [51] Usual communication 37 (median) per
site at 82 sites
Frequent email contact
and individual feedback
about recruitment to
the recruiter
37.5 (median) per
site at 85 sites
RR, experimental recruitment strategy/standard recruitment strategy.
aStudies showed a statistically significant difference in consent rates between recruitment strategies.
doi:10.1371/journal.pmed.1000368.t004
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that increased trial participation. There were insufficient data to
evaluate whether the effects of the different recruitment strategies
were constant across all health conditions, but no there was no
clear trend for these strategies to be context specific (see Table 1).
The recruitment trials on how recruitment information was
provided (the technique of information presentation, how
information was framed, who presented the information, and
when the information was presented) did not show a difference
between strategies, demonstrating that how or when the
information was presented or who presented the information did
not influence recruitment, but rather the information provided. A
recent study (which was published after completion of our last
search update) also showed that publicity about the trial did not
increase recruitment [51].
Although a previous observational study showed that framing of
recruitment information to emphasise uncertainty enhanced
recruitment [52], when this was tested by the rigor of RCT
methodology [49,50], we found that framing did not appear to
influence recruitment. Unexpectedly we found that the role of the
recruiter also did not show evidence of influencing recruitment
(although costs were higher for senior recruiters [28,29]).
Table 5. Studies of incentives.
Study
Standard
Recruitment Strategy n/N
Consent Rate
(95% CI)
Experimental
Recruitment Strategies n/N
Consent Rate
(95% CI)
RR
(95% CI)
Martinson [6] No incentives 288/996 29% (26–32) US$2 small prepaid cash 423/1,021 41% (38–45) 1.43
(1.19–1.72)
a
Large cash incentives
contingent on response
(US$15)
452/1,021 44% (41–47) 1.53
(1.28–1.84)
a
US$200 prize draw 397/1008 39% (36–42) 1.36
(1.13–1.64)
a
Halpern [47] A-10%
risk of adverse effect
US$100 26/64 41% (29–54) US$1,000 33/64 52% (39–64) 0.76
(0.45–1.30)
US$100 26/64 41% (29–54) US$2,000 35/64 55% (42–67) 0.72
(0.43–1.21)
US$1,000 33/64 52% (39–64) US$2,000 35/64 55% (42–67) 0.94
(0.60–1.48)
Halpern [47] A-20%
risk of adverse effect
US$100 23/64 36% (24–49) US$1,000 26/64 41% (29–54) 0.92
(0.30–1.70)
US$100 23/64 36% (24–49) US$2,000 29/64 45% (33–58) 0.80
(0.45–1.43)
US$1,000 26/64 41% (29–54) US$2,000 29/64 45% (33–58) 0.87
(0.50–1.51)
Halpern [47] A-30%
risk of adverse effect
US$100 18/64 28% (18–41) US$1,000 23/64 36% (24–49) 0.75
(0.37–1.53)
US$100 18/64 28% (18–41) US$2,000 25/64 39% (27–52) 0.69
(0.35–1.39)
US$1,000 23/64 36% (24–49) US$2,000 25/64 39% (27–52) 0.92
(0.50–1.70)
Halpern [47] B- 10%
assigned to placebo
US$100 21/62 34% (22–47) US$1,000 27/62 44% (31–57) 0.79
(0.43–1.45)
US$100 21/62 34% (22–47) US$2,000 28/62 45% (33–58) 0.70
(0.43–1.45)
US$1,000 27/62 44% (31–57) US$2,000 28/62 45% (33–58) 1.00
(0.58–1.73)
Halpern [47] B- 30%
assigned to placebo
US$100 20/62 32% (21–45) US$1,000 25/62 40% (28–54) 0.77
(0.40–1.48)
US$100 20/62 32% (21–45) US$2,000 26/62 42% (30–55) 0.77
(0.40–1.48)
US$1,000 25/62 40% (28–54) US$2,000 26/62 42% (30–55) 1.00
(0.56–1.80)
Halpern [47] B- 50%
assigned to placebo
US$100 19/62 31% (20–44) US$1,000 23/62 37% (25–50) 0.83
(0.42–1.64)
US$100 19/62 31% (20–44) US$2,000 27/62 44% (31–57) 0.71
(0.38–1.36)
US$1,000 23/62 37% (25–50) US$2,000 27/62 44% (31–57) 0.86
(0.48–1.54)
RR, experimental recruitment strategy/standard recruitment strategy. Used total number/number of experimental strategies to calculate RR, so that standard was not
overrepresented. Halpern’s study used each participant more than once.
aStudies showed a statistically significant difference in consent rates between recruitment strategies.
doi:10.1371/journal.pmed.1000368.t005
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noninferiority clinical study (with active treatment arms) had
higher consent rates compared with a placebo-controlled clinical
study. This finding is consistent with previous findings that patients
preferred ‘‘trials with all active arms to placebo-controlled trials’’
[53]. Also, recruitment trials that compared standard placebo-
controlled design with a nonblinded trial design demonstrated that
patients were more willing to participate in a clinical study if they
knew which treatment they were receiving when consenting, even
if the treatment was randomly predetermined. These studies
illustrate people’s anxieties regarding the unknowns of clinical trial
participation. Despite the higher consent rates for the nonblinded
trial design, the differential loss to follow up in the two treatments
arms of the nonblinded trial is likely to jeopardise validity of the
results, as comparison of outcomes between the two treatment
groups would be subject to selection bias. For example, patients
may be more likely to drop out if they were unhappy with the
treatment they were assigned. In the two included studies of
nonblinded trial designs, there were higher drop outs in the active
treatment arms compared with the placebo arms.
The inclusion of recruitment trials of recruitment to mock
clinical studies enabled assessment of recruitment strategies, which
for equity reasons would be difficult to compare (such as different
randomisation designs, different monetary incentives). Some
strategies may be acceptable when used in isolation, but
inappropriate when more than one are used within the same
clinical study: for example mock trials that tested the hypothesis
that potential participants are more willing to participate in a study
if they had an increased chance of receiving the experimental
treatment is a strategy that has been adopted by many vaccine and
other clinical studies in the belief that potential participants are
more likely to participate if they believed they had a higher chance
of receiving the (desirable) experimental treatment. However, we
found that increasing the likelihood of receiving the experimental
treatment [19] (or reducing the risk of receiving placebo) [14] did
not appear to affect the consent rate, demonstrating that people’s
decisions for clinical study participation are not influenced by
whether they are more or less likely to receive a particular
treatment. Other strategies are more controversial: for example,
the only consent strategy that appeared to affect the consent rate
for a mock trial was ‘‘prerandomisation to standard drug’’ [18],
where participants were given the standard drug and nonpartic-
ipants were given the experimental drug. Fewer people were
willing to consent to this type of clinical study than to a clinical
study of standard randomisation for all participants. It is unlikely
that such a method could ethically be employed in a real situation.
Monetary incentives appeared to increase consent compared to no
monetary incentives [31], but the amount of money appeared to
be less important [14].
As results of mock clinical studies are based on whether
participants are willing to enrol in a clinical study (rather than
whether they actually consented), extrapolation to real clinical
studies may not be realistic. Stated ‘‘willingness to participate’’
and actual participation may also differ. In the recruitment trial
comparing standard consent to the addition of a video
explaining clinical trial information and the health problem
studied for a mock clinical study, although statistically more
participants from the video group were willing to enrol in the
clinical study, this number became not statistically significant
2 wk later [44]. Conversely, in Sime’s 1986 study [49], more
participants actually consented to clinical study participation
than had indicated willingness to participate, perhaps reflecting
patients’ deference to doctors’ advice in the 1980s (when there
w a sl e s se m p h a s i so np a t i e n ta u t o n o m yc o m p a r e dw i t ht o d a y ) .I t
also showed the influence of the doctor on patient behaviour
[53].
Figure 6. Consent rates for methods of providing information. RR, intervention recruitment strategy/standard recruitment strategy. Used
total number/number of intervention strategies to calculate RR, so that the number of patients on standard strategies were not overrepresented; S,
standard informed consent; B, bulk mailing; 1, enhanced recruitment letter and screening by African American interviewer; 2, enhanced recruitment
letter, screening by African American interviewer and baseline information collected via telephone interview; 3, enhanced recruitment letter,
screening by African American interviewer and church-based project sessions; 4, bulk mailing with letter; 5, first-class mailing; 6, first-class mailing
with letter.
doi:10.1371/journal.pmed.1000368.g006
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strategies to enhance recruitment to research [9,10], our study is
the latest and has a more targeted and rigorous search method.
We conducted a more comprehensive search (with inclusion of
more databases than Watson’s study [10]) and included earlier as
well as later studies, and also studies of recruitment for mock trials
Table 6. Studies of methods of providing information.
Study
Standard
Recruitment
Strategy n/N
Consent
Rate
(95% CI)
Experimental
Recruitment
Strategies n/N
Consent
Rate
(95% CI) RR (95% CI)
Kendrick [4] Standard informed
consent (mailing)
157/1,194 13% (11–15) Additional home safety
questionnaire
217/1,203 18% (16–20) 1.37 (1.14–1.66)
a
Kiernan [28] Standard informed
consent
(mailing of flyer)
0/191 0% (0–2) Additional personal letter
(combination of general
letter+Hispanic specific letter)
9/370 2% (1–5) 9.83 (0.58–168.04)
Valanis [34] Standard informed
consent (mailing)
225/11,273 2% (2–6) Advanced postcard 1 wk prior
to mailing of recruitment packet
226/11,273 2% (2–2) 1.0 (0.84–1.21)
Nystuen [31] Standard informed
consent (mailing)
42/347 12% (9–16) Additional reminder phone call
for nonresponders
55/356 15% (12–19) 1.28 (0.88–1.85)
Ford [25] Standard informed
consent (mailing)+
screening
b
95/3,297 3% (2–4) Enhanced recruitment letter+
screening by African American
interviewer
78/3,079 3% (2–3) 0.87 (0.58–1.31)
Enhanced recruitment letter+
screening by African American
interviewer+baseline information
collected via telephone interview
87/3,075 3% (2–3) 0.97 (0.65–1.45)
Enhanced recruitment letter+
screening by African American
interviewer+church-based project
sessions
116/2,949 4% (3–5) 1.35 (0.92–1.99)
Tworoger
[37]
Bulk mailing no
letters
86/1,250 7% (6–8) Bulk mailing with letter 87/1,251 7% (6–9) 1.00 (0.67–1.50)
First class mailing no letters 102/1,249 8% (7–10) 1.17 (0.79–1.75)
First class mailing with letters 101/1,249 8% (7–10) 1.16 (0.78–1.73)
Leira [29] Standard informed
consent
25/50 50% (36–65) Advanced notification with
phone and fax
27/50 54% (39–68) 1.08 (0.74–1.57)
Llewellyn-
Thomas [2]
Tape recording of
trial information
21/50 42% (28–57) Interactive computer program
for participants
31/50 62% (47–75) 1.48 (1.00–2.18)
a
Weston [5] Standard informed
consent
17/48 35% (22–51) Additional video about the
health condition
26/42 62% (46–76) 1.75 (1.11–2.74)
a
Berner [45] Standard informed
consent (verbal)
4/50 7% (2–19) Additional written
cancer-specific information
4/56 7% (2–17) 0.89 (0.24–3.38)
Ellis [24] Standard informed
consent
14/42 33% (20–50) Additional education booklet
on trials
12/41 29% (16–46) 0.88 (0.46–1.66)
Du [39] Standard informed
consent
10/63 16% (8–27) Additional video about
clinical trials
16/63 25% (15–38) 1.60 (0.79–3.25)
Hutchison [38] Standard informed
consent
66/87 76% (66–84) AVPI tool to explain about
trials, video+DVD/CD
62/86 72% (61–81) 0.95 (0.80–1.13)
Coyne [48] Standard informed
consent
93/137 68% (59–76) Easy-to-read consent
statement
67/89 75% (65–84) 1.11(0.94–1.31)
Wadland [35] Patients reading
trial information
25/53 47% (33–61) Study coordinator reading and
explaining the study to patients
27/51 53% (39–67) 1.12 (0.76–1.65)
Aaronson [20] Standard informed
consent
78/90 87% (78–93) Additional phone-based contact
with oncology nurse
68/90 76% (65–84) 0.87 (0.76–1.01)
Mandelblatt [3] Standard informed
consent (brochure)
147/218 67% (61–74) Additional brief educational session
and discussion about the trial
178/232 77% (71–82) 1.14 (1.01–1.28)
a
Simes [33] Total disclosure 23/28 82% (63–94) Individual approach 27/29 93% (77–99) 1.13 (0.93–1.38)
Wragg [44] Explicit information
c 8/26 31% (14–52) Ambiguous information
d 14/24 58% (37–78) 1.90 (0.97–3.70)
RR, experimental recruitment strategy/standard recruitment strategy. Used total number/number of experimental strategies to calculate RR, so that standard was not
overrepresented.
aStudies showed a statistically significant difference in consent rates between recruitment strategies.
bStandard informed consent and screening (used total number/number of experimental strategies to calculate RR, so that standard was not overrepresented).
cProvides the current best estimates of effect of the experimental treatment.
dEmphasises the current state of uncertainty.
doi:10.1371/journal.pmed.1000368.t006
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compare for equity reasons. Our methods were also more rigorous
(with two reviewers examining all titles, abstracts, and relevant
papers) with an inclusion criteria targeting recruitment of
participants for RCTs only (excluding studies about recruitment
to observational studies, questionnaires, health promotional
activities. and other health care interventions). We targeted
recruitment to RCTs in which recruitment is more difficult
because potential participants must consent to participation in
research in which their treatment is unknown. The Mapstone
study conducted in 2002 and published in 2007 [9] included
recruitment for any type of research studies, and the Watson study
[10], although targeting recruitment strategies used for RCTs,
searched only from 1996 to 2004 with a limited number of
electronic databases (without hand searching), using only the
keywords ‘‘recruitment strategy’’ or ‘‘recruitment strategies.’’ Our
study has identified more studies than the previous reviews (37
compared with 14 and 15 studies), and provides a better
understanding of the factors that influence clinical RCT
participation for potential participants. Although both previous
studies highlighted effective and ineffective strategies, there was no
attempt to examine the differences between successful and
unsuccessful recruitment strategies.
Our findings are consistent with the health belief model that
people are more likely to adopt a health behaviour (such as
participation in a clinical study) if they perceive they are at risk of a
significant health problem [54]. The importance of informing
potential participants about the health problem being studied and
engaging them in the learning process is not only educational and
constructive, but is also likely to enhance clinical trial participa-
tion.
Limitations
Because of major differences in recruitment methods, popula-
tions, and types of clinical studies that were recruiting as well as
outcomes measured, we did not combine the results statistically in
a meta-analysis. In many of the smaller recruitment trials, the
failure to find a significant difference in consent rates could be
related to the sample size (type II error). There may also be
publication bias. However, as more than 70% (27/37) of the
included studies had a nonsignificant result, we are hopeful that
publication bias may be minimal. Given that the interventions we
are considering are of noncommercial value we would suggest that
publication bias may be less likely than for other interventions.
The majority of the included trials were conducted in developed
countries, with a substantial proportion in the US. We
acknowledge that developed countries’ health systems may be
very different from those of less-developed countries and hence the
results of this systematic review may not be generalizable to other
countries.
The main limitation of the study, due to the prolonged conduct
of the study (from 2000 to 2009), was that the search strategy had
to be modified with subsequent search updates owing to changes
in MEDLINE Mesh heading definitions. Because of these changes
(and the large number of titles and abstracts searched), the reason
for exclusion of each study cannot be provided. The abstract of the
first version of this systematic review (which included nonrando-
mised studies owing to the lack of randomised recruitment trials on
the subject at the time) was published in conference proceedings in
2002 [11], and a later version that was limited to randomised
studies was published in conference proceedings in 2007 [12].
Conclusion
Our systematic review of recruitment strategies for enhancing
participation in clinical RCTs has identified a number of effective
and ineffective recruitment strategies. Grouped together, the
statistically significant strategies either engaged participants in
learning about the health problem being studied and its impact on
their health or else informed participants of the treatment they
have been randomised to receive (nonblinded trial design).
However, as there was differential loss to follow up in the different
treatment arms with nonblinded trial design, this trial design is
likely to jeopardise the validity of the results. The use of monetary
incentives may also increase recruitment, but as this was tested in a
mock trial, and as another mock trial did not show any difference
in consent rates between different amounts of monetary incentives,
this finding needs to be interpreted with caution.
Future RCTs of recruitment strategies that engaged participants
in the learning process using various methods of delivering the
recruitment material compared with standard recruitment may
confirm the effectiveness of this concept. This research may be
particularly useful for testing strategies that expose large number
of potential participants to recruitment information such as
interactive internet strategies.
Supporting Information
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Found at: doi:10.1371/journal.pmed.1000368.s001 (0.07 MB
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Background. Before any health care intervention—a
treatment for a disease or a measure such as vaccination
that is designed to prevent an illness—is adopted by the
medical community, it undergoes exhaustive laboratory-
based and clinical research. In the laboratory, scientists
investigate the causes of diseases, identify potential new
treatments or preventive methods, and test these
interventions in animals. New interventions that look
hopeful are then investigated in clinical trials—studies that
test these interventions in people by following a strict trial
protocol or action plan. Phase I trials test interventions in a
few healthy volunteers or patients to evaluate their safety
and to identify possible side effects. In phase II trials, a larger
group of patients receives an intervention to evaluate its
safety further and to get an initial idea of its effectiveness. In
phase III trials, very large groups of patients (sometimes in
excess of a thousand people) are randomly assigned to
receive the new intervention or an established intervention
or placebo (dummy intervention). These ‘‘randomized
controlled trials’’ or ‘‘RCTs’’ provide the most reliable
information about the effectiveness and safety of health
care interventions.
Why Was This Study Done? Patients who participate in
clinical trials must fulfill the inclusion criteria laid down in the
trial protocol and must be given information about the trial,
its risks, and potential benefits before agreeing to participate
(informed consent). Unfortunately, many RCTs struggle to
enroll the number of patients specified in their trial protocol,
which can reduce a trial’s ability to measure the effect of a
new intervention. Inadequate recruitment can also increase
costs and, in the worst cases, prevent trial completion.
Several strategies have been developed to improve
recruitment but it is not clear which strategy works best. In
this study, the researchers undertake a systematic review (a
study that uses predefined criteria to identify all the research
on a given topic) of ‘‘recruitment trials’’—studies that have
randomly divided potential RCT participants into groups,
applied different strategies for recruitment to each group,
and compared recruitment rates in the groups.
What Did the Researchers Do and Find? The researchers
identified 37 randomized trials of recruitment strategies into
real and mock RCTs (where no actual trial occurred). In all,
18,812 people agreed to participate in an RCT in these
recruitment trials out of at least 59,354 people approached.
Some of these trials investigated novel strategies for
recruitment, such as changes in how patients are
randomized. Others looked at the effect of recruiter
differences (for example, increased contact between the
health care professionals doing the recruiting and the trial
investigators), the effect of offering monetary incentives to
participants, and the effect of giving more information about
the trial to potential participants. Recruitment strategies that
improved people’s awareness of the health problem being
studied—provision of an interactive computer program or a
video about the health condition, attendance at an
educational session, or inclusion of a health questionnaire
in the recruitment process—improved recruitment rates, as
did monetary incentives. Increasing patients’ understanding
about the trial process itself, recruiter differences, and
alterations in consent design and randomization generally
had no effect on recruitment rates although consent rates
were higher when patients knew the treatment to which
they had been randomly allocated before consenting.
However, differential losses among the patients in different
treatment groups in such nonblinded trials may jeopardize
study findings.
What Do These Findings Mean? These findings suggest
that trial recruitment strategies that focus on increasing the
awareness of potential participants of the health problem
being studied and its possible effects on their health, and
that engage potential participants in the trial process are
likely to increase recruitment to RCTs. The accuracy of these
findings depends on whether the researchers identified all
the published research on recruitment strategies and on
whether other research on recruitment strategies has been
undertaken and not published that could alter these
findings. Furthermore, because about half of the recruit-
ment trials identified by the researchers were undertaken in
the US, the successful strategies identified here might not
be generalizable to other countries. Nevertheless, these
recruitment strategies should now be investigated further
to ensure that the future evaluation of new health care
interventions is not hampered by poor recruitment into
RCTs.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/
10.1371/journal.pmed.1000368.
N The ClinicalTrials.gov Web site is a searchable register of
federally and privately supported clinical trials in the US
and around the world, providing information about all
aspects of clinical trials
N The US National Institutes of Health provides information
about clinical trials
N The UK National Health Service Choices Web site has
information for patients about clinical trials and medical
research
N The UK Medical Research Council Clinical Trials Units also
provides information for patients about clinical trials and
links to information on clinical trials provided by other
organizations
N MedlinePlus has links to further resources on clinical trials
(in English and Spanish)
N The Australian Government’s National Health and Medical
Research Council has information about clinical trials
N WHO International Clinical Trials Registry Platform aims to
ensure that all trials are publicly accessible to those making
health care decisions
N The Star Child Health – International Forum of Standards
for Research is a resource center for pediatric clinical trial
design, conduct, and reporting
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